Overview

Molecular Phenotype Changes and Personalized Treatment for CRPC

Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
To explore the molecular phenotypic changes and personalized treatment in castration-resistant prostate cancer.
Phase:
N/A
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Treatments:
Cisplatin
Docetaxel
Etoposide
Etoposide phosphate
Prednisone